Page last updated: 2024-10-27

foscarnet and Hematologic Malignancies

foscarnet has been researched along with Hematologic Malignancies in 6 studies

Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.

Research Excerpts

ExcerptRelevanceReference
"An unusually high incidence of acyclovir- and foscarnet-resistant herpes simplex virus (HSV) infection was noted after lymphocyte-depleted blood hematopoietic progenitor cell (HPC) transplantation from HLA-haploidentical family donors."3.71Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. ( Allen, A; Bucur, S; Caliendo, AM; Cherry, J; Hutcherson, D; Langston, AA; Lonial, S; Redei, I; Somani, J; Waller, EK, 2002)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (66.67)29.6817
2010's1 (16.67)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Yu, HC1
Liu, WD1
Kuo, PH1
Lin, CC1
Wu, UI1
Didsbury, MS1
Mackie, FE1
Kennedy, SE1
Hebart, H1
Brugger, W1
Grigoleit, U1
Gscheidle, B1
Loeffler, J1
Schäfer, H1
Kanz, L1
Einsele, H1
Sinzger, C1
Kiehl, MG1
Basara, N1
Chakrabarti, S1
Collingham, KE1
Osman, H1
Fegan, CD1
Milligan, DW1
Langston, AA1
Redei, I1
Caliendo, AM1
Somani, J1
Hutcherson, D1
Lonial, S1
Bucur, S1
Cherry, J1
Allen, A1
Waller, EK1

Reviews

1 review available for foscarnet and Hematologic Malignancies

ArticleYear
A systematic review of acute kidney injury in pediatric allogeneic hematopoietic stem cell recipients.
    Pediatric transplantation, 2015, Volume: 19, Issue:5

    Topics: Acute Kidney Injury; Adolescent; Amphotericin B; Biomarkers; Child; Cyclosporine; Foscarnet; Glomeru

2015

Trials

1 trial available for foscarnet and Hematologic Malignancies

ArticleYear
Cidofovir for cytomegalovirus-preemptive therapy in stem cell transplant recipients.
    Blood, 2001, Sep-01, Volume: 98, Issue:5

    Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resistance,

2001

Other Studies

4 other studies available for foscarnet and Hematologic Malignancies

ArticleYear
Cutaneous presentation of disseminated cytomegalovirus infection in a non-transplant patient with hematological malignancy: A case report.
    Medicine, 2022, Feb-04, Volume: 101, Issue:5

    Topics: Antiviral Agents; Cytomegalovirus Infections; Fatal Outcome; Foscarnet; Ganciclovir; Hematologic Neo

2022
Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality.
    Blood, 2001, Apr-01, Volume: 97, Issue:7

    Topics: Adult; Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalovirus Infections; F

2001
Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.
    Bone marrow transplantation, 2001, Volume: 28, Issue:9

    Topics: Adult; Antiviral Agents; Cidofovir; Cyclosporine; Cytomegalovirus; Cytomegalovirus Infections; Cytos

2001
Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation.
    Blood, 2002, Feb-01, Volume: 99, Issue:3

    Topics: Acyclovir; Adult; Antiviral Agents; Drug Resistance, Viral; Female; Foscarnet; Haplotypes; Hematolog

2002